Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.

Breitling LP, Koenig W, Fischer M, Mallat Z, Hengstenberg C, Rothenbacher D, Brenner H.

PLoS One. 2011;6(7):e22318. doi: 10.1371/journal.pone.0022318. Epub 2011 Jul 22.

2.

The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.

Shuvalova YA, Khasanova ZB, Kaminnaya VI, Samoilova EV, Korotaeva AA, Rubanovich AV, Kaminnyi AI.

Gene. 2015 Jun 10;564(1):29-34. doi: 10.1016/j.gene.2015.03.030. Epub 2015 Mar 17.

PMID:
25794429
3.

Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.

Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D.

Eur Heart J. 2009 Nov;30(22):2742-8. doi: 10.1093/eurheartj/ehp302. Epub 2009 Aug 7.

PMID:
19666896
4.

Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.

Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EP, Li M, Leusink M, Trompet S, Verschuren JJ, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van 't Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JM, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day IN, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JC, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Paré G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJ.

J Am Coll Cardiol. 2013 Nov 19;62(21):1966-76. doi: 10.1016/j.jacc.2013.06.044. Epub 2013 Jul 31.

5.

Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study.

Wootton PT, Drenos F, Cooper JA, Thompson SR, Stephens JW, Hurt-Camejo E, Wiklund O, Humphries SE, Talmud PJ.

Hum Mol Genet. 2006 Jan 15;15(2):355-61. Epub 2005 Dec 20.

PMID:
16368710
6.

Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.

O'Donoghue ML, Mallat Z, Morrow DA, Benessiano J, Sloan S, Omland T, Solomon SD, Braunwald E, Tedgui A, Sabatine MS.

Clin Chem. 2011 Sep;57(9):1311-7. doi: 10.1373/clinchem.2011.166520. Epub 2011 Jul 22.

7.

C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.

Hartford M, Wiklund O, Mattsson Hultén L, Persson A, Karlsson T, Herlitz J, Caidahl K.

J Intern Med. 2007 Nov;262(5):526-36. Epub 2007 Oct 1.

8.

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.

Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD; PLASMA Investigators..

Lancet. 2009 Feb 21;373(9664):649-58. doi: 10.1016/S0140-6736(09)60403-7. Erratum in: Lancet.2011 Apr 30;377(9776):1494. Lancet. 2009 May 9-2009 May15;373(9675):1606.

PMID:
19231633
9.

Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.

Divchev D, Grothusen C, Luchtefeld M, Thoenes M, Onono F, Koch R, Drexler H, Schieffer B.

Eur Heart J. 2008 Aug;29(16):1956-65. doi: 10.1093/eurheartj/ehn276. Epub 2008 Jun 18.

PMID:
18565968
10.

Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.

Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H.

Circulation. 1999 Sep 21;100(12):1280-4.

11.

Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.

Menschikowski M, Hagelgans A, Fuessel S, Mareninova OA, Asatryan L, Wirth MP, Siegert G.

Inflamm Res. 2013 Dec;62(12):1063-72. doi: 10.1007/s00011-013-0665-5. Epub 2013 Sep 24.

PMID:
24061501
12.

Opposite effects of native and oxidized lipoproteins on the activity of secretory phospholipase A(2) group IIA.

Korotaeva AA, Samoilova EV, Pirkova AA, Ameliushkina VA, Prokazova NV, Tkachuk VA, Chazov EI.

Prostaglandins Other Lipid Mediat. 2009 Nov;90(1-2):37-41. doi: 10.1016/j.prostaglandins.2009.07.004. Epub 2009 Jul 30.

PMID:
19647092
13.

Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.

Rothenbacher D, Hoffmann MM, Breitling LP, Rajman I, Koenig W, Brenner H.

BMC Cardiovasc Disord. 2013 Aug 27;13:61. doi: 10.1186/1471-2261-13-61.

14.

Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Sullivan CP, Seidl SE, Rich CB, Raymondjean M, Schreiber BM.

J Biol Chem. 2010 Jan 1;285(1):565-75. doi: 10.1074/jbc.M109.070565. Epub 2009 Oct 22.

15.

Group II subfamily secretory phospholipase A2 enzymes: expression in chronic rhinosinusitis with and without nasal polyps.

Liu Z, Lu X, Wang H, You XJ, Gao QX, Cui YH.

Allergy. 2007 Sep;62(9):999-1006. Epub 2007 Jun 18.

16.

Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.

Exeter HJ, Folkersen L, Palmen J, Franco-Cereceda A, Cooper JA, Kalea AZ, Hooft FV, Eriksson P, Humphries SE, Talmud PJ.

PLoS One. 2012;7(7):e41139. doi: 10.1371/journal.pone.0041139. Epub 2012 Jul 17.

17.
18.

Phospholipases A2 in normal human conjunctiva and from patients with primary open-angle glaucoma and exfoliation glaucoma.

Helin M, Rönkkö S, Puustjärvi T, Teräsvirta M, Uusitalo H.

Graefes Arch Clin Exp Ophthalmol. 2008 May;246(5):739-46. doi: 10.1007/s00417-007-0757-4. Epub 2008 Jan 15.

PMID:
18196260
19.

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.

Rosenson RS, Fraser H, Goulder MA, Hislop C.

Cardiovasc Drugs Ther. 2011 Dec;25(6):539-44. doi: 10.1007/s10557-011-6344-2.

PMID:
21989792
20.

Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community.

Kaess BM, Preis SR, Lieb W, Beiser AS, Yang Q, Chen TC, Hengstenberg C, Erdmann J, Schunkert H, Seshadri S, Vasan RS; CARDIoGRAM., Assimes TL, Deloukas P, Holm H, Kathiresan S, König IR, McPherson R, Reilly MP, Roberts R, Samani NJ, Stewart AF.

J Am Heart Assoc. 2015 Mar 11;4(3):e001544. doi: 10.1161/JAHA.114.001544. Erratum in: J Am Heart Assoc. 2016 Jul;5(7). pii: e002098. doi: 10.1161/JAHA.116.002098.

Supplemental Content

Support Center